Showing results (891-900 of 967) with videos related to
Sort By:
Pageof 97
Hepatology Research : the Official Journal of the Japan Society of Hepatology|November 20, 2021
Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysisAtsushi Hiraoka, Takashi Kumada, Toshifumi Tada, et al.European Heart Journal. Cardiovascular Pharmacotherapy|January 25, 2020
Practical guidance for P2Y12 inhibitors in acute myocardial infarction undergoing percutaneous coronary interventionSeung Hun Lee, Hyun Kuk Kim, Myung Ho Jeong, et al.Cancer Medicine|April 20, 2022
Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Journal of Gastroenterology and Hepatology|October 15, 2019
Real-world experience of 12-week direct-acting antiviral regimen of glecaprevir and pibrentasvir in patients with chronic hepatitis C virus infectionHidenori Toyoda, Masanori Atsukawa, Tsunamasa Watanabe, et al.Cancer Medicine|December 9, 2022
New prognostic system based on inflammation and liver function predicts prognosis in patients with advanced unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: A validation studyToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Cancer Medicine|September 26, 2022
The hepatocellular carcinoma modified Gustave Roussy Immune score (HCC-GRIm score) as a novel prognostic score for patients treated with atezolizumab and bevacizumab: A multicenter retrospective analysisTakeshi Hatanaka, Atsushi Naganuma, Atsushi Hiraoka, et al.Hepatology Research : the Official Journal of the Japan Society of Hepatology|January 26, 2022
Association of early bevacizumab interruption with efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma: A landmark analysisTakeshi Hatanaka, Atsushi Hiraoka, Toshifumi Tada, et al.European Journal of Gastroenterology & Hepatology|February 16, 2022
Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysisToshifumi Tada, Takashi Kumada, Atsushi Hiraoka, et al.Circulation Journal : Official Journal of the Japanese Circulation Society|June 3, 2021
Impact of Chronic Kidney Disease on In-Hospital and 3-Year Clinical Outcomes in Patients With Acute Myocardial Infarction Treated by Contemporary Percutaneous Coronary Intervention and Optimal Medical Therapy - Insights From the J-MINUET StudyYousuke Hashimoto, Yukio Ozaki, Shino Kan, et al.JAMA Cardiology|February 14, 2019
Association of Genetic and Clinical Aspects of Congenital Long QT Syndrome With Life-Threatening Arrhythmias in Japanese PatientsWataru Shimizu, Hisaki Makimoto, Kenichiro Yamagata, et al.Pageof 97